IEOP Issue Diabetes Awareness Month

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Expert Opinion on Pharmacotherapy

at Taylor & Francis

Expert Opinion on Pharmacotherapy is proud to present Pharmacotherapy for diabetes and its complications.

Expert Opinion on Pharmacotherapy (EOP) has launched a special focus issue on Pharmacotherapy for Diabetes and its complications in honor of both of the US's National Diabetes Awareness Month and the upcoming World Diabetes Day (the 14th of November). To connect our readers with diabetes experts around the world and to celebrate the issue launch we invite you to read a selection of articles which have been made freely available for a limited time

Expert Opinion on Pharmacotherapy a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases. If you are interested in publishing with us, please do not hesitate to contact Commissioning Editor David Grech ([email protected]) or by submitting to


A snapshot of EOP’s Metrics:

3.889 (2020) Impact Factor

Q2 (2020) Impact Factor Best Quartile

5.1 (2020) CiteScore


Please Note: You can publish in 3 weeks from submission with Accelerated Publication.


 In honor of Diabetes Awareness Month Expert Opinion on Pharmacotherapy is making the below articles free to access. Feel free to browse at your leisure. 




In honor of Diabetes Awareness Month feel free to browse the articles listed below:

Careful use to minimize adverse events of oral antidiabteic medications in the elderly

An increasing number of older patients has type 2 diabetes treated with different oral antidiabetic agents whose safety may raise concern considering some particularities of a heterogeneous elderly population.


Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?

Cluster analysis has identified distinct groups of type 2 diabetes (T2D) subjects with distinct metabolic characteristics. Thus, personalizing pharmacologic therapy to individual phenotypic and pathophysiologic characteristics has potential to improve metabolic control and reduce risk of microvascular and macrovascular complications.


Novel approaches to pharacological management of type 2 diabetes in Japan

Newly developed anti-diabetic medications have had multiple activities, beyond a blood glucose-lowering effect. Current drugs for treating type 2 diabetes mellitus (T2DM) are based on the use of gastrointestinal hormones. Representative incretin preparations, such as those with glucagon-like peptide (GLP)-1 or gastric inhibitory polypeptide (GIP) activity, aim to provide new means of controlling blood glucose levels, body weight, and lipid metabolism.


Sodium-glucose cotransporter 2 inhibitors for the management of type 2 diabetes

Sodium−glucose cotransporter (SGLT) 2 inhibitors reduce glucose reabsorption in the kidney, increase glucosuria, and improve glycemia. Besides glycemic efficacy, the class also lowers risk of cardiovascular and renal disease.


Synthetic long-acting insulin analogs for the management of type 1 diabetes: an update

Type 1 diabetes is characterized by insulin deficiency and requires near-physiological insulin replacement. In most patients, this is accomplished by basal bolus therapy consisting of a long-acting basal insulin administered once or twice daily and short-acting insulin with main meals. Several long-acting insulin analogs have been developed to optimize basal insulin therapy.






Latest tweets from @tandfstem